- Low dose voclosporin achieves CR rate of 49.4% at 48 weeks (p<.001)
- AURORA Phase III trial with low dose voclosporin on track to commence in Q2 2017
ir.auriniapharma.com...s-releases/detail/73
seekingalpha.com/art...even-better-expected
- AURORA Phase III trial with low dose voclosporin on track to commence in Q2 2017
ir.auriniapharma.com...s-releases/detail/73
seekingalpha.com/art...even-better-expected